Y-mAbs Therapeutics (YMAB) announced that the first patient has been administered both the first protein dose and the Lu-DOTA imaging dose in ...

The two companies worked together on blood cancer blockbuster Darzalex (daratumumab) – a CD38-targeting antibody which brought in almost $12 billion in sales worldwide last year – but J&J has ...

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

Y-mAbs' naxitamab shows promise in treating high-risk neuroblastoma. Explore its phase 2 success, strong cash runway, and growth potential. Learn more on YMAB stock here.

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...

(RTTNews) - Genmab A/S (GMAB) Monday announced that Johnson & Johnson (JNJ) has decided not to exercise its option to develop and commercialize HexaBody-CD38 for multiple myeloma, for a worldwide ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...